Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction

Annals of Pharmacotherapy

Volumn 41, Issue 5, 2007, Pages 737-741

  Dorsch, Michael P ^a   Jin, Sun Lee ^b   Lynch, Donald R ^b   Dunn, Steven P ^c   Rodgers, Jo E ^d   Schwartz, Todd ^e   Colby, Emily ^e   Montague, Debbie ^f   Smyth, Susan S ^c,g  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e IL   (United States)

^f University of North Carolina   (United States)

^g Gill Heart Vascular Institute   (United States)

Author keywords

Aspirin resistance; Coronary artery disease; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HEART INFARCTION; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

AGED; ASPIRIN; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEX FACTORS;

EID: 34248530551     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H621     Document Type: Article

References (12)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-93.
3. Martin CP, Talbert RL. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 2005;25:942-53.
4. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
5. Coleman J, Wang JC, Simon JI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care 2004;3:77-82.
6. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
7. Helgason CM, Bolin KM, Hoff J A, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
8. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
9. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
10. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000;18:629-42.
11. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585-95.
12. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006;295:1420-7.